Syndax to Host ASH Investor Event in Person and via Webcast on December 8, 2025

Rhea-AI Summary

Syndax Pharmaceuticals (Nasdaq: SNDX) will host an in-person investor event with a live webcast on Monday, December 8, 2025 at 7:00 a.m. ET during the 67th American Society of Hematology (ASH) Annual Meeting.

Company management and multiple key opinion leaders will discuss data updates from the Revuforj (revumenib) and Niktimvo (axatilimab-csfr) programs. A live webcast and a replay will be available on the Investor section of the company website at www.syndax.com for a limited time.

News Market Reaction

+0.44% 1.6x vol

68 alerts

+0.44% News Effect

+10.0% Peak Tracked

-23.1% Trough Tracked

+$6M Valuation Impact

$1.36B Market Cap

1.6x Rel. Volume

On the day this news was published, SNDX gained 0.44%, reflecting a mild positive market reaction. Argus tracked a peak move of +10.0% during that session. Argus tracked a trough of -23.1% from its starting point during tracking. Our momentum scanner triggered 68 alerts that day, indicating high trading interest and price volatility. This price movement added approximately $6M to the company's valuation, bringing the market cap to $1.36B at that time. Trading volume was above average at 1.6x the daily average, suggesting increased trading activity.

Data tracked by StockTitan Argus on the day of publication.

NEW YORK, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the Company will host an in-person investor event, along with a live webcast, on Monday, December 8, 2025, at 7:00 a.m. ET during the 67^th American Society of Hematology (ASH) Annual Meeting. Members of the Syndax management team will be joined by multiple key opinion leaders to discuss data updates from the Company’s Revuforj^® (revumenib) and Niktimvo™ (axatilimab-csfr) programs.

A live webcast of the event will be available on the Investor section of the Company's website at www.syndax.com, where a replay of the event will also be available for a limited time.

About Syndax

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies. Highlights of the Company's pipeline include Revuforj^® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor. Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X and LinkedIn.

Syndax Contacts

Sharon Klahre
Syndax Pharmaceuticals, Inc.
sklahre@syndax.com
Tel 781.684.9827

SNDX-G

FAQ

When is the Syndax (SNDX) investor event at ASH 2025?

The event is scheduled for Monday, December 8, 2025 at 7:00 a.m. ET during the 67th ASH Annual Meeting.

How can I watch the Syndax (SNDX) ASH investor presentation if I cannot attend in person?

A live webcast will be available on the Investor section of www.syndax.com, with a replay posted for a limited time.

What programs will Syndax (SNDX) discuss at the December 8, 2025 event?

Management and key opinion leaders will discuss data updates for Revuforj (revumenib) and Niktimvo (axatilimab-csfr).

Where is the Syndax (SNDX) investor event being held during ASH 2025?

The event will be held in person during the 67th American Society of Hematology Annual Meeting; a live webcast will also be offered.

Will the Syndax (SNDX) webcast be available after the live event?

Yes. A replay will be available on the company's Investor website for a limited time.